{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:27:02Z","timestamp":1791332822830,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The study aims to conduct a meta-analysis on 5-year survival rate and mortality-related factors in the patients with primary Sj\u00f6gren\u2019s syndrome concomitant with interstitial lung disease (pSS-ILD). Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched various platforms and databases until November 22, 2023. We used the Newcastle\u2013Ottawa Scale (NOS) for quality assessment and extracted study characteristics and effect sizes. The pooled 5-year survival rate, hazard ratios (HRs), and the corresponding 95% confidence intervals (95% CIs) were then calculated. A p-value of less than 0.05 was considered statistically significant. Patients with pSS-ILD. Mortality in patients with pSS-ILD. Out of 188 articles, seven met the inclusion criteria. The meta-analysis estimated a 5-year survival rate of 82% (73%-91%). Mortality-related factors estimated by the meta-analysis included older age (HRs\u2009=\u20091.06, 95% CI 1.03\u20131.09,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001), history of smoking (HRs\u2009=\u20093.44, 95% CI 2.14\u20135.53,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.00001), anti-SSA antibody positivity (HRs\u2009=\u20090.41, 95% CI 0.20\u20130.85,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02), anti-SSB antibody positivity (HRs\u2009=\u20090.42, 95% CI 0.18\u20130.98,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04), reduced forced vital capacity (FVC; HRs\u2009=\u20090.96, 95% CI 0.95\u20130.98,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001), reduced 6-min walk distance (6MWD; HRs\u2009=\u20090.99, 95% CI 0.99\u20131.00,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0008), presence of a reticular abnormality (HRs\u2009=\u20093.03, 95% CI 1.54\u20135.95,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001), and decreased arterial partial pressure of oxygen (PaO\n                    <jats:sub>2<\/jats:sub>\n                    ) levels (HRs\u2009=\u20090.99, 95% CI 0.97\u20131.00,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04). The 5-year survival rate for pSS-ILD is 82%. Older age, history of smoking, anti-SSA antibody negativity, anti-SSB antibody negativity, reduced FVC, reduced 6MWD, presence of a reticular abnormality, and decreased PaO\n                    <jats:sub>2<\/jats:sub>\n                    levels increase the mortality risk in pSS-ILD.\n                  <\/jats:p>","DOI":"10.1007\/s10067-024-07191-0","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T07:02:16Z","timestamp":1729494136000},"page":"23-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Meta-analysis of mortality-associated factors in primary Sj\u00f6gren\u2019s syndrome patients with interstitial lung disease"],"prefix":"10.1007","volume":"44","author":[{"given":"Ruochen","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5290-9734","authenticated-orcid":false,"given":"Xuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"7191_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/eos.12536","volume":"126","author":"R Jonsson","year":"2018","unstructured":"Jonsson R, Brokstad KA, Jonsson MV et al (2018) Current concepts on Sj\u00f6gren\u2019s syndrome-classification criteria and biomarkers. Eur J Oral Sci 126:37\u201348. https:\/\/doi.org\/10.1111\/eos.12536","journal-title":"Eur J Oral Sci"},{"issue":"2","key":"7191_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102447","volume":"19","author":"G Sambataro","year":"2020","unstructured":"Sambataro G, Ferro F, Orlandi M et al (2020) Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sj\u00f6gren\u2019s syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev 19(2):102447. https:\/\/doi.org\/10.1016\/j.autrev.2019.102447","journal-title":"Autoimmun Rev"},{"key":"7191_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7191_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554\u2013558. https:\/\/doi.org\/10.1136\/ard.61.6.554","journal-title":"Ann Rheum Dis"},{"key":"7191_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Primary Sj\u00f6gren\u2019s Syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol Hoboken NJ 69:35\u201345. https:\/\/doi.org\/10.1002\/art.39859","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"7191_CR6","unstructured":"Wells GA, Shea B, O\u2019Connell D et al (2022) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 1 Dec 2022"},{"key":"7191_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"7191_CR8","doi-asserted-by":"publisher","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10:Ed000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","DOI":"10.1002\/14651858.ED000142"},{"key":"7191_CR9","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1038\/s41598-022-09283-w","volume":"12","author":"YJ Kim","year":"2022","unstructured":"Kim YJ, Choe J, Moon SJ et al (2022) Blood KL-6 predicts prognosis in primary Sj\u00f6gren\u2019s syndrome-associated interstitial lung disease. Sci Rep 12:5343. https:\/\/doi.org\/10.1038\/s41598-022-09283-w","journal-title":"Sci Rep"},{"key":"7191_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105811","volume":"159","author":"Y Kamiya","year":"2019","unstructured":"Kamiya Y, Fujisawaet T, Konoal M et al (2019) Prognostic factors for primary Sj\u00f6gren\u2019s syndrome-associated interstitial lung diseases. Respir Med 159:105811. https:\/\/doi.org\/10.1016\/j.rmed.2019.105811","journal-title":"Respir Med"},{"issue":"35","key":"7191_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026777","volume":"100","author":"H Gao","year":"2021","unstructured":"Gao H, Sun Y, Zhang XY et al (2021) Characteristics and mortality in primary Sj\u00f6gren syndrome-related interstitial lung disease. Medicine (Baltimore) 100(35):e26777. https:\/\/doi.org\/10.1097\/MD.0000000000026777","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"7191_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/atm.atm_632_20","volume":"16","author":"EH Alhamad","year":"2021","unstructured":"Alhamad EH, Cal JG, Alrajhi NN et al (2021) Clinical characteristics and outcomes in patients with primary Sjogren\u2019s syndrome-associated interstitial lung disease. Ann Thorac Med 16(2):156\u2013164. https:\/\/doi.org\/10.4103\/atm.atm_632_20","journal-title":"Ann Thorac Med"},{"key":"7191_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073774","volume":"8","author":"Y Enomoto","year":"2013","unstructured":"Enomoto Y, Takemura T, Hagiwara E et al (2013) Prognostic factors in interstitial lung disease associated with primary Sj\u00f6gren\u2019s syndrome: A retrospective analysis of 33 pathologically-proven cases. PLoS ONE 8:e73774. https:\/\/doi.org\/10.1371\/journal.pone.0073774","journal-title":"PLoS ONE"},{"issue":"12","key":"7191_CR14","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/1756-185X.14023","volume":"23","author":"Y Xu","year":"2020","unstructured":"Xu Y, Zhou J, Dong X et al (2020) Risk factors for progression and prognosis of primary Sj\u00f6gren\u2019s syndrome-associated interstitial lung disease in a Chinese population. Int J Rheum Dis 23(12):1734\u20131740. https:\/\/doi.org\/10.1111\/1756-185X.14023","journal-title":"Int J Rheum Dis"},{"issue":"24","key":"7191_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011003","volume":"97","author":"H Gao","year":"2018","unstructured":"Gao H, Zhang XW, He J et al (2018) Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sj\u00f6gren syndrome patients. Medicine 97(24):e110. https:\/\/doi.org\/10.1097\/MD.0000000000011003","journal-title":"Medicine"},{"key":"7191_CR16","doi-asserted-by":"publisher","unstructured":"Cho SJ, Stout-Delgado HW (2019) Aging and lung disease. Annu Rev Physiol 82(1). https:\/\/doi.org\/10.1146\/annurev-physiol-021119-034610","DOI":"10.1146\/annurev-physiol-021119-034610"},{"key":"7191_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2022","unstructured":"Moss BJ, Ryter SW, Rosas IO (2022) Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol 17:515\u2013546. https:\/\/doi.org\/10.1146\/annurev-pathol-042320-030240","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"7191_CR18","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s10067-019-04906-6","volume":"39","author":"T Zhang","year":"2020","unstructured":"Zhang T, Yuan F, Xu L et al (2020) Characteristics of patients with primary Sj\u00f6gren\u2019s syndrome associated interstitial lung disease and relevant features of disease progression. Clin Rheumatol 39(5):1561\u20131568. https:\/\/doi.org\/10.1007\/s10067-019-04906-6","journal-title":"Clin Rheumatol"},{"key":"7191_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","volume":"16","author":"F Roca","year":"2017","unstructured":"Roca F, Dominique S, Schmidt J et al (2017) Interstitial lung disease in primary Sjogren\u2019s syndrome. Autoimmun Rev 16:48\u201354. https:\/\/doi.org\/10.1016\/j.autrev.2016.09.017","journal-title":"Autoimmun Rev"},{"key":"7191_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.etap.2017.10.001","volume":"56","author":"Y Hu","year":"2017","unstructured":"Hu Y, Wang LS, Li Y et al (2017) Effects of particulate matter from straw burning on lung fibrosis in mice. Environ Toxicol Pharmacol 56:249\u2013258. https:\/\/doi.org\/10.1016\/j.etap.2017.10.001","journal-title":"Environ Toxicol Pharmacol"},{"key":"7191_CR21","doi-asserted-by":"publisher","unstructured":"Luppi F, Kalluri M, Faverio P et al (2021) Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir Res 22(1). https:\/\/doi.org\/10.1186\/s12931-021-01711-1","DOI":"10.1186\/s12931-021-01711-1"},{"key":"7191_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:431\u2013440. https:\/\/doi.org\/10.1164\/rccm.201006-0894CI","journal-title":"Am J Respir Crit Care Med"},{"key":"7191_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10067-021-05984-1","volume":"41","author":"SH He","year":"2022","unstructured":"He SH, He YJ, Guo KJ et al (2022) Risk factors for progression of interstitial lung disease in Sj\u00f6gren\u2019s syndrome: a single-centered, retrospective study. Clin Rheumatol 41:1153\u20131161. https:\/\/doi.org\/10.1007\/s10067-021-05984-1","journal-title":"Clin Rheumatol"},{"key":"7191_CR24","doi-asserted-by":"publisher","first-page":"1901747","DOI":"10.1183\/13993003.01747-2019","volume":"55","author":"OA Shlobin","year":"2020","unstructured":"Shlobin OA, Kouranos V, Barnett SD et al (2020) Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: Results from an international registry. Eur Respir J 55:1901747. https:\/\/doi.org\/10.1183\/13993003.01747-2019","journal-title":"Eur Respir J"},{"key":"7191_CR25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.rmed.2013.04.002","volume":"107","author":"AE Holland","year":"2013","unstructured":"Holland AE, Hill CJ, Glaspole I et al (2013) Impaired chronotropic response to 6-min walk test and reduced survival in interstitial lung disease. Respir Med 107:1066\u20131072. https:\/\/doi.org\/10.1016\/j.rmed.2013.04.002","journal-title":"Respir Med"},{"key":"7191_CR26","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL et al (2018) American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 198:e44\u2013e68. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST","journal-title":"Am J Respir Crit Care Med"},{"key":"7191_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1164\/rccm.200403-417OC","volume":"171","author":"I Ito","year":"2005","unstructured":"Ito I, Nagai S, Kitaichi M et al (2005) Pulmonary manifestations of primary Sjogren\u2019s syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 171:632\u2013638. https:\/\/doi.org\/10.1164\/rccm.200403-417OC","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07191-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T08:39:38Z","timestamp":1736757578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07191-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7191"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07191-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}